Consensus screening for a challenging target: the quest for P-glycoprotein inhibitors

Paolo Governa, Marco Biagi,Fabrizio Manetti,Stefano Forli

DOI: https://doi.org/10.26434/chemrxiv-2023-cq1h6

2023-11-08

Abstract:ATP-binding cassette (ABC) transporters are a large family of proteins involved in membrane transport of a wide variety of substrates. Among them, ABCB1, also known as MDR-1 or P-glycoprotein (P-gp), is the most characterized. By exporting xenobiotics out of the cell, P-gp activity can affect the ADME properties of several drugs. Moreover, P-gp has been found to mediate multidrug resistance in cancer cells. Thus, the inhibition of P-gp activity may lead to increased absorption and/or intracellular accumulation of co-administered drugs, enhancing their effectiveness. Using the human cryoEM 3D structure of the P-gp in the inhibitor-bound intermediate form (PDBID: 6qee), approximately 200'000 commercially available natural compounds from the ZINC database were virtually screened. To build a model able to discriminate between substrate and inhibitors, two datasets of compounds with known activity, including P-gp inhibitors, substrates, and inactive molecules were also docked. The best docking pose of selected substrates and inhibitors were used to generate 3D common feature pharmacophoric models that were combined with the Autodock Vina binding energy values to prioritize compounds for visual inspection. With this consensus approach, 13 potential candidates were identified and then tested for their ability to inhibit P-gp, using zosuquidar, a P-gp inhibitor of clinical use, as a reference drug. Eight compounds were found to be active with 6 of them having an IC50 lower than 5 µM in a membrane-based ATPase activity assay. Moreover, the P-gp inhibitory activity was also confirmed by two different cell-based in vitro methods. These results demonstrate the ability of the combined structure-based pharmacophore modeling and docking-based virtual screening approach to predict novel hit compounds with inhibitory activity toward P-gp. The resulting chemical scaffolds could serve as inspiration for the optimization of novel and more potent P-gp inhibitors.

Chemistry

What problem does this paper attempt to address?

The aim of this paper is to address the development of a structure-based pharmacophore modeling and molecular docking virtual screening method to identify novel compounds with inhibitory activity against P-glycoprotein (P-gp). P-glycoprotein is an important drug efflux transporter whose activity affects the absorption, distribution, metabolism, and excretion (ADME) properties of various drugs and can lead to multidrug resistance in tumor cells. Therefore, discovering effective P-gp inhibitors can enhance drug efficacy and oral bioavailability. By combining pharmacophore models and molecular docking methods, the researchers hope to find new chemical scaffolds as a basis for optimizing novel P-gp inhibitors. Specifically, the paper utilizes the cryo-electron microscopy structure of human P-gp (PDBID: 6qee) to virtually screen approximately 200,000 commercially available natural compounds and validates the screening results through in vitro experiments.

Consensus screening for a challenging target: the quest for P-glycoprotein inhibitors

Consensus screening for a challenging target: the quest for P-glycoprotein inhibitors

Computationally accelerated identification of P-glycoprotein inhibitors

Homology Modeling of the Human P-glycoprotein (ABCB1) and Insights into Ligand Binding through Molecular Docking Studies

Mechanistic insights into P-glycoprotein ligand transport and inhibition revealed by enhanced molecular dynamics simulations

Structure–Function Relationships in the Human P-Glycoprotein (ABCB1): Insights from Molecular Dynamics Simulations

Tracing the substrate translocation mechanism in P-glycoprotein

Admet Evaluation in Drug Discovery. 13. Development of in Silico Prediction Models for P-Glycoprotein Substrates

Designing potent inhibitors against the multidrug resistance P-glycoprotein

Exploring the Dynamics of the ABCB1 Membrane Transporter P-glycoprotein in the Presence of ATP and Active/Non-active Compounds through Molecular Dynamics Simulations

Molecular Modeling Studies to Probe the Binding Hypothesis of Novel Lead Compounds against Multidrug Resistance Protein ABCB1

Identification and Empiric Evaluation of New Inhibitors of the Multidrug Transporter P-Glycoprotein (ABCB1)

Screening and Analysis of Possible Drugs Binding to PDGFRα: A Molecular Modeling Study

Establishment of a P-glycoprotein Substrate Screening Model and Its Preliminary Application

Structural insight into substrate and inhibitor discrimination by human P-glycoprotein

Simultaneous Binding Mechanism of Multiple Substrates for Multidrug Resistance Transporter P-glycoprotein.

Model of P-Glycoprotein Ligand Binding and Validation with Efflux Substrate Matched Pairs

Discovery of Inhibitors Targeting Protein Tyrosine Phosphatase 1B Using a Combined Virtual Screening Approach

Selectivity profiling of BCRP versus P-gp inhibition: from automated collection of polypharmacology data to multi-label learning

Probing the Druggablility on the Interface of the Protein–Protein Interaction and Its Allosteric Regulation Mechanism on the Drug Screening for the CXCR4 Homodimer

Chemical molecular‐based approach to overcome multidrug resistance in cancer by targeting P‐glycoprotein (P‐gp)